Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • BerGenBio ASA News

    0,0126 € 0,00% +0,00 €
    08:00:14 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2DPC0
    ISIN: NO0010650013
    US-Symbol: BRRGF
    Typ: Aktie

    BerGenBio ASA News

    25.08.21 - DGAP
    BerGenBio (BGBIO): Martin Olin succeeds Richard Godfrey as CEO
    Edison Investment Research Limited BerGenBio (BGBIO): Martin Olin succeeds Richard Godfrey as CEO 25-Aug-2021 / 08:16 GMT/BST London, UK, 25 August 2021 BerGenBio ...
    23.08.21 - DGAP
    Edison Investment Research Limited: BerGenBio (BGBIO): Advancing towards pivotal studies
    Edison Investment Research Limited Edison Investment Research Limited: BerGenBio (BGBIO): Advancing towards pivotal studies 23-Aug-2021 / 07:00 GMT/BST London, UK, 23 ...
    12.07.21 - PR Newswire
    BerGenBio Presents Encouraging Combined Data for Bemcentinib from Two Phase II COVID-19 Studies at ECCMID
    BerGenBio Presents Encouraging Combined Data for Bemcentinib from Two Phase II COVID-19 Studies at ECCMID PR Newswire
    16.06.21 - DGAP
    BerGenBio (BGBIO): FDA grants fast track designation
    Edison Investment Research Limited BerGenBio (BGBIO): FDA grants fast track designation 16-Jun-2021 / 07:00 GMT/BST London, UK, 16 June 2021 BerGenBio (BGBIO): FDA ...
    11.06.21 - PR Newswire
    Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting
    Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting PR Newswire
    11.06.21 - PR Newswire
    Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting
    Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting Encouraging updated preliminary survival data ...
    18.05.21 - PR Newswire
    BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients
    BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients PR Newswire
    18.05.21 - PR Newswire
    BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients
    BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients The trial BGBC020 shows that Bemcentinib has the potential to ...
    21.04.21 - DGAP
    BerGenBio (BGBIO): Bemcentinib preliminary data in COVID-19
    Edison Investment Research Limited BerGenBio (BGBIO): Bemcentinib preliminary data in COVID-19 21-Apr-2021 / 07:00 GMT/BST London, UK, 21 April 2021 BerGenBio ...
    19.04.21 - PR Newswire
    BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients
    BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients PR Newswire
    19.04.21 - PR Newswire
    BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients
    BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients Day 29 follow-up of last patient enrolled has now ...
    06.03.21 - PR Newswire
    BerGenBio Presents Preclinical COVID-19 Data at Annual Conference on Retroviruses and Opportunistic Infections (CROI 2021)
    BerGenBio Presents Preclinical COVID-19 Data at Annual Conference on Retroviruses and Opportunistic Infections (CROI 2021) PR Newswire
    04.03.21 - PR Newswire
    Bergenbio Closes Recruitment Into Trial Assessing Bemcentinib In Covid-19 Patients
    Bergenbio Closes Recruitment Into Trial Assessing Bemcentinib In Covid-19 Patients PR Newswire
    27.02.21 - DGAP
    BerGenBio (BGBIO): AXLeration of data catalysts in 2021
    Edison Investment Research Limited BerGenBio (BGBIO): AXLeration of data catalysts in 2021 27-Feb-2021 / 07:00 GMT/BST London, UK, 27 February 2021 BerGenBio (BGBIO) ...
    17.02.21 - PR Newswire
    BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021)
    BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021) PR Newswire
    17.02.21 - PR Newswire
    BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021)
    BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021) PR Newswire
    17.12.20 - DGAP
    BerGenBio (BGBIO): Progressing towards key inflection points
    Edison Investment Research Limited BerGenBio (BGBIO): Progressing towards key inflection points 17-Dec-2020 / 08:00 GMT/BST London, UK, 17 December 2020 BerGenBio ...
    06.12.20 - PR Newswire
    BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020
    BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 PR Newswire
    06.12.20 - PR Newswire
    BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020
    BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 - Clinical benefit rate of 73% reported in second line ...
    17.11.20 - DGAP
    BerGenBio (BGBIO): Initiation - Bemcentinib leading the AXL charge
    Edison Investment Research Limited BerGenBio (BGBIO): Initiation - Bemcentinib leading the AXL charge 17-Nov-2020 / 14:59 GMT/BST London, UK, 17 November 2020 ...

    Newssuche

    Videos

    26.04.24 -6,97%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »